Search research articles
Contact Us
Filters
Showing results (91-100 of 106) with videos related to
Page
of 11
Sort By:
Intensive Care Medicine
|
June 30, 2026
The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis
Michael Ruzicka, Hans Christian Stubbe, Josia Fauser, et al.
Leukemia & Lymphoma
|
September 2, 2011
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
Clemens-Martin Wendtner, Peter Hillmen, Daruka Mahadevan, et al.
The Lancet. Oncology
|
September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Othman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
Blood
|
March 5, 2016
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
Sascha Dietrich, Andreas Pircher, Volker Endris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 24, 2021
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
Alina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, et al.
European Journal of Pediatrics
|
May 4, 2026
Risk factors for severe post-COVID condition in children, adolescents, and young adults
Quirin Donath, Matthias Haegele, Daniela Schindler, et al.
Hemasphere
|
February 20, 2020
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, et al.
Nature Communications
|
February 22, 2018
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D Herling, Nima Abedpour, Jonathan Weiss, et al.
The New England Journal of Medicine
|
June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Kirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 106) with videos related to
Sort By:
Page
of 11
Intensive Care Medicine
|
June 30, 2026
The HLH-Risk-Calculator is a machine learning-based tool to predict course & mortality of secondary hemophagocytic lymphohistiocytosis
Michael Ruzicka, Hans Christian Stubbe, Josia Fauser, et al.
Leukemia & Lymphoma
|
September 2, 2011
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia
Clemens-Martin Wendtner, Peter Hillmen, Daruka Mahadevan, et al.
The Lancet. Oncology
|
September 5, 2020
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Othman Al-Sawaf, Can Zhang, Maneesh Tandon, et al.
Blood
|
March 5, 2016
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib
Sascha Dietrich, Andreas Pircher, Volker Endris, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
June 24, 2021
Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
Alina Tscherne, Jan Hendrik Schwarz, Cornelius Rohde, et al.
European Journal of Pediatrics
|
May 4, 2026
Risk factors for severe post-COVID condition in children, adolescents, and young adults
Quirin Donath, Matthias Haegele, Daniela Schindler, et al.
Hemasphere
|
February 20, 2020
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG)
Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, et al.
Nature Communications
|
February 22, 2018
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D Herling, Nima Abedpour, Jonathan Weiss, et al.
The New England Journal of Medicine
|
June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Kirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.
Page
of 11